Discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects

Journal of Clinical Pharmacology

Volumn 46, Issue 7, 2006, Pages 802-811

  Straka, Robert J ^a   Burkhardt, R Todd ^a   Lang, Nicholas P ^b   Hadsall, Kelly Z ^c   Tsai, Michael Y ^d  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c NORTH MEMORIAL MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Caffeine; Genotype; Hmong; N acetyltransferase 2; Phenotype

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; CAFFEINE;

ACETYLATION; ADULT; AGED; ALLELE; ARTICLE; DNA POLYMORPHISM; DNA PROBE; EVALUATION; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; MALE; METABOLITE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PHENOTYPE; POPULATION GENETICS; POPULATION RESEARCH; URINALYSIS;

ACETYLATION; ADULT; ARYLAMINE N-ACETYLTRANSFERASE; ASIAN AMERICANS; CAFFEINE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LAOS; MALE; MIDDLE AGED; MINNESOTA; PHENOTYPE; SEQUENCE ANALYSIS, DNA;

EID: 33745075602     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006288955     Document Type: Article

References (54)

1. Nebert DW. Suggestions for the nomenclature of human alleles: relevance to ecogenetics, pharmacogenetics and molecular epidemiology. Pharmacogenetics. 2000;10:279-290.
2. Hutchings A, Routledge PA. A simple method for determining acetylator phenotype using isoniazid. Br J Clin Pharmacol. 1986;22:343-345.
3. Evans DA, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. Br Med J. 1960:5197:485-491.
4. Tang BK, Kadar D, Kalow W. An alternative test for acetylator phenotyping with caffeine. Clin Pharmacol Ther. 1987;42:509-513.
5. Grant DM, Tang BK, Kalow W. A simple test for acetylator phenotype using caffeine. Br J Clin Pharmacol. 1984;17:459-464.
6. Weber WW, Hein DW. Clinical pharmacokinetics of isoniazid. Clin Pharmacokinet 1979;4:401-422.
7. Blum M, Grant DM, McBride W, Heim M, Meyer UA. Human arylamine N-acetyltransferase genes: isolation, chromosomal localization, and functional expression. DNA Cell Biol. 1990;9:193-203.
8. Ebisawa T, Deguchi T. Structure and restriction fragment length polymorphism of genes for human liver arylamine N-acetyltransferases. Biochem Biophys Res Commun. 1991;177:1252-1257.
9. Hein DW. Human NAT2 alleles. Available at: http://www. louisville.edu/medschool/pharmacology/NAT2.html. Accessed September 22, 2005.
10. Hein DW. Arylamine N-acetyltransferase (NAT) nomenclature. Available at: http://www.louisville.edu/medschool/pharmacology/NAT.html. Accessed October 3, 2005.
11. Vatsis KP, Weber WW, Bell DA, et al. Nomenclature for N-acetyltransferases. Pharmacogenetics. 1995;5:1-17.
12. Lin HJ, Han CY, Lin BK, Hardy S. Slow acetylator mutations in the human polymorphic N-acetyltransferase gene in 786 Asians, blacks, Hispanics, and whites: application to metabolic epidemiology. Am J Hum Genet. 1993;52:827-834.
13. Bell DA, Taylor JA, Butler MA, et al. Genotype/phenotype discordance for human arylamine N-acetyltransferase (NAT2) reveals a new slow-acetylator allele common in African-Americans. Carcinogenesis. 1993;14:1689-1692.
14. Delomenie C, Sica L, Grant DM, Krishnamoorthy R, Dupret JM. Genotyping of the polymorphic N-acetyltransferase (NAT2*) gene locus in two native African populations. Pharmacogenetics. 1996;6:177-185.
15. Straka RJ, Burkhardt RT, Lang NP, Hadsall KZ, Vang T, Tsai MY. Predominance of slow acetylator phenotype for N-acetyltransferase (NAT2) in a Hmong population. Pharmacotherapy. 2004;24:1459.
16. TB statistics. Minnesota Department of Health Web site. Available at: http://www.health.state.mn.us/divs/idepc/diseases/ tb/stats.html. Accessed October 3, 2005.
17. Ross JA, Xie Y, Kiffmeyer WR, Bushhouse S, Robison LL. Cancer in the Minnesota Hmong population. Cancer. 2003;97:3076-3079.
18. Straka RJ, Hansen SR, Benson SR, Walker PF. Predominance of slow acetylators of N-acetyltransferase in a Hmong population residing in the United States. J Clin Pharmacol. 1996;36:740-747.
19. Horai Y, Zhou HH, Zhang LM, Ishizaki T. N-acetylation phenotyping with dapsone in a mainland Chinese population. Br J Clin Pharmacol. 1988;25:81-87.
20. Le Marchand L, Sivaraman L, Franke AA, et al. Predictors of N-acetyltransferase activity: should caffeine phenotyping and NAT2 genotyping be used interchangeably in epidemiological studies? Cancer Epidemiol Biomarkers Prev. 1996;5:449-455.
21. Lee SY, Lee KA, Ki CS, et al. Complete sequencing of a genetic polymorphism in NAT2 in the Korean population. Clin Chem. 2002;48:775-777.
22. Hashiguchi M, Ebihara A. Acetylation polymorphism of caffeine in a Japanese population. Clin Pharmacol Ther. 1992;52: 274-276.
23. Zaid RB, Nargis M, Neelotpol S, et al. Acetylation phenotype status in a Bangladeshi population and its comparison with that of other Asian population data. Biopharm Drug Dispos. 2004;25: 237-241.
24. Kukongviriyapan V, Lulitanond V, Areejitranusorn C, Kongyingyose B, Laupattarakasem P. N-acetyltransferase polymorphism in Thailand. Hum Hered. 1984;34:246-249.
25. Andrisin TE, Humma LM, Johnson JA. Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies. Pharmacotherapy. 2002;22:954-960.
26. Butler MA, Lang NP, Young JF, et al. Determination of CYP1A2 and NAT2 phenotypes in human populations by analysis of caffeine urinary metabolites. Pharmacogenetics. 1992;2:116-127.
27. Nyeki A, Buclin T, Biollaz J, Decosterd LA. NAT2 and CYP1A2 phenotyping with caffeine: head-to-head comparison of AFMU vs. AAMU in the urine metabolite ratios. Br J Clin Pharmacol. 2003;55:62-67.
28. Cascorbi I, Drakoulis N, Brockmoller J, Maurer A, Sperling K, Roots I. Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet. 1995;57:581-592.
29. Rozen S, Skaletsky HJ. Primer3 on the WWW for general users and for biologist programmers. Bioinformatics Methods and Protocols: Methods in Molecular Biology. Totowa, NJ: Humana Press; 2000.
30. Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Wheeler DL. GenBank: update. Nucleic Acids Res. 2004;32(Database issue): D23-D26.
31. Tatusova TA, Madden TL. BLAST 2 Sequences, a new tool for comparing protein and nucleotide sequences. FEMS Microbiol Lett. 1999;174:247-250.
32. O'Reilly Network. Available at: http://www.perl.com/. Accessed September 26, 2005.
33. Rosner B. Fundamentals of Biostatistics. Pacific Grove, Calif: Duxbury Press; 2000.
34. Wallace B. Basic Population Genetics. New York, NY: Columbia University Press; 1981.
35. Mrozikiewicz PM, Drakoulis N, Roots I. Polymorphic arylamine N-acetyltransferase (NAT2) genes in children with insulin-dependent diabetes mellitus. Clin Pharmacol Ther. 1994; 56:626-634.
36. Hickman D, Sim E. N-acetyltransferase polymorphism: comparison of phenotype and genotype in humans. Biochem Pharmacol. 1991;42:1007-1014.
37. Graf T, Broly F, Hoffmann F, Probst M, Meyer UA, Howald H. Prediction of phenotype for acetylation and for debrisoquine hydroxylation by DNA-tests in healthy human volunteers. Eur J Clin Pharmacol. 1992;43:399-403.
38. Blum M, Demierre A, Grant DM, Heim M, Meyer UA. Molecular mechanism of slow acetylation of drugs and carcinogens in humans. Proc Natl Acad Sci U S A. 1991;88:5237-5241.
39. Gross M, Kruisselbrink T, Anderson K, et al. Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol Biomarkers Prev. 1999; 8:683-692.
40. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther. 1993;53:503-514.
41. Tang BK, Kadar D, Qian L, Iriah J, Yip J, Kalow W. Caffeine as a metabolic probe: validation of its use for acetylator phenotyping. Clin Pharmacol Ther. 1991;49:648-657.
42. Kadlubar FF, Butler MA, Kaderlik KR, Chou HC, Lang NP. Polymorphisms for aromatic amine metabolism in humans: relevance for human carcinogenesis. Environ Health Perspect. 1992;98:69-74.
43. Wohlleb JC, Hunter CF, Blass B, Kadlubar FF, Chu DZ, Lang NP. Aromatic amine acetyltransferase as a marker for colorectal cancer: environmental and demographic associations. Int J Cancer. 1990;46:22-30.
44. Hosking L, Lumsden S, Lewis K, et al. Detection of genotyping errors by Hardy-Weinberg equilibrium testing. Eur J Hum Genet. 2004;12:395-399.
45. Hein DW, Ferguson RJ, Doll MA, Rustan TD, Gray K. Molecular genetics of human polymorphic N-acetyltransferase: enzymatic analysis of 15 recombinant wild-type, mutant, and chimeric NAT2 allozymes. Hum Mol Genet. 1994;3:729-734.
46. Bolt HM, Selinski S, Dannappel D, Blaszkewicz M, Golka K. Re-investigation of the concordance of human NAT2 phenotypes and genotypes. Arch Toxicol. 2005;79:196-200.
47. Grant DM, Hughes NC, Janezic SA, et al. Human acetyltransferase polymorphisms. Mutat Res. 1997;376:61-70.
48. Butcher NJ, Boukouvala S, Sim E, Minchin RF. Pharmacogenetics of the arylamine N-acetyltransferases. Pharmacogenomics J. 2002;2:30-42.
49. Hein DW, Doll MA, Fretland AJ, et al. Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev. 2000;9:29-42.
50. O'Neil WM, Drobitch RK, MacArthur RD, et al. Acetylator phenotype and genotype in patients infected with HIV: discordance between methods for phenotype determination and genotype. Pharmacogenetics. 2000;10:171-182.
51. Boukouvala S, Sim E. Structural analysis of the genes for human arylamine N-acetyltransferases and characterisation of alternative transcripts. Basic Clin Pharmacol Toxicol. 2005;96:343-351.
52. Kalow W, Tang BK. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther. 1991;50:508-519.
53. Dew TP, Day AJ, Morgan MR. Xanthine oxidase activity in vitro: effects of food extracts and components. J Agric Food Chem. 2005;53:6510-6515.
54. Becquemont L, Chazouilleres O, Serfaty L, et al. Effect of interferon alpha-ribavirin bitherapy on cytochrome P450 1A2 and 2D6 and N-acetyltransferase-2 activities in patients with chronic active hepatitis C. Clin Pharmacol Ther. 2002;71:488-495.